Patents by Inventor Shixiang JIA

Shixiang JIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240301063
    Abstract: The invention provided herein relates to methods and uses of a bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests.
    Type: Application
    Filed: May 22, 2024
    Publication date: September 12, 2024
    Inventors: Qiang Li, Shixiang Jia, Lili Zhao, Guimin Zhang, Zhong Liu, Xinlu Ma, Yuan Yan, Zhenyu Li, Xingxia Hu, Yuhua Zhang, Bin Li
  • Publication number: 20240254187
    Abstract: The present disclosure relates to a dual-function protein for regulating blood glucose and lipid metabolism, wherein said dual-function protein comprises a human GLP-1 analog and human FGF21. In the present disclosure, provided is a method for preparing said dual function protein, and also provided is the use of said dual-function protein in the preparation of a biological substance for treating type 2 diabetes, obesity, dyslipidemia, fatty liver disease and/or metabolic syndrome. The dual-function protein provided in the present disclosure can synergistically regulate blood glucose and lipid levels in vivo, and satisfy multiple requirements for patients with type 2 diabetes such as lowering blood glucose, relieving hepatic steatosis, reducing body weight and improving metabolic disorders of circulating lipids.
    Type: Application
    Filed: April 2, 2024
    Publication date: August 1, 2024
    Applicant: AMPSOURCE BIOPHARMA SHANGHAI INC.
    Inventors: Zhao DONG, Chi ZHOU, Xiong FENG, Jiyu ZHANG, Shixiang JIA, Qiang LI
  • Patent number: 12039733
    Abstract: A method for identifying an individual of an oplegnathus punctatus based on a convolutional neural network is provided. Target initial positioning involves three continuous convolutional layers and an average pooling layer. A region of feature interest point is obtained, a hyperparameter candidate box is set to obtain a region, thereby obtaining an approximate position of a target object. II_Net backbone convolutional neural network includes six convolutional layers and four pooling layers, which includes a LeakyReLU activation function used as an activation function of the first convolutional layer, convolutional network layers of Alexnet and parameter data, and a maximum pooling layer of an overlapped pooling structure. Fully connected layers use a genetic algorithm to improve data transmission between layers. With the established model, identification of the individual of the oplegnathus punctatus is performed by using test data.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: July 16, 2024
    Assignee: Ludong University
    Inventors: Jun Yue, Beibei Li, Shixiang Jia, Zhenbo Li, Qing Wang, Zheng Ma, Guangjie Kou, Tao Yao, Zhenzhong Li
  • Patent number: 12030939
    Abstract: The invention provided herein relates to methods and uses of a bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: July 9, 2024
    Assignee: Shandong New Time Pharmaceutical Co., Ltd.
    Inventors: Qiang Li, Shixiang Jia, Lili Zhao, Guimin Zhang, Zhong Liu, Xinlu Ma, Yuan Yan, Zhenyu Li, Xingxia Hu, Yuhua Zhang, Bin Li
  • Patent number: 11981718
    Abstract: The present disclosure relates to a dual-function protein for regulating blood glucose and lipid metabolism, wherein said dual-function protein comprises a human GLP-1 analog and human FGF21. In the present disclosure, provided is a method for preparing said dual function protein, and also provided is the use of said dual-function protein in the preparation of a biological substance for treating type 2 diabetes, obesity, dyslipidemia, fatty liver disease and/or metabolic syndrome. The dual-function protein provided in the present disclosure can synergistically regulate blood glucose and lipid levels in vivo, and satisfy multiple requirements for patients with type 2 diabetes such as lowering blood glucose, relieving hepatic steatosis, reducing body weight and improving metabolic disorders of circulating lipids.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: May 14, 2024
    Assignee: AMPSOURCE BIOPHARMA SHANGHAI INC.
    Inventors: Zhao Dong, Chi Zhou, Xiong Feng, Jiyu Zhang, Shixiang Jia, Qiang Li
  • Publication number: 20230416385
    Abstract: A bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests. The method for constructing a bispecific antibody is simple, and avoids the possibility of mismatching between two sets of light chains and heavy chains of a heterologous bispecific antibody, thus the difficulty of antibody purification is reduced, the affinity of the obtained antibody is high, the side effects of induced cytokines are few, and safety is high.
    Type: Application
    Filed: September 26, 2019
    Publication date: December 28, 2023
    Inventors: Qiang Li, Shixiang Jia, Lili Zhao, Guimin Zhang, Zhong Liu, Xinlu Ma, Yuan Yan, Zhenyu Li, Xingxia Hu, Yuhua Zhang, Bin Li
  • Patent number: 11790640
    Abstract: Disclosed is a method for detecting densely occluded fish based on a YOLOv5 network, belonging to the technical field of fish images. The method includes a data set establishment and processing part, a model training part and a model testing part; the data set establishment and processing part includes data collection of fish pictures, data labelling and data division of the fish pictures; and the data division is to divide data into a training set, a verification set and a test set.
    Type: Grant
    Filed: March 15, 2023
    Date of Patent: October 17, 2023
    Assignee: Ludong University
    Inventors: Jun Yue, Cheng Dong, Zhenbo Li, Jun Zhang, Guangjie Kou, Shixiang Jia, Ning Li, Hao Sun
  • Patent number: 11694428
    Abstract: Disclosed is a method for detecting Ophiocephalus argus cantor under intra-class occulusion based on cross-scale layered feature fusion, including image collecting, image processing and network model, where collected images are labeled, image sizes are adjusted to obtain input images, and the input images are input into an object detection network, integrated by convolution and inserted into cross-scale layered feature fusion modules, characterized by including dividing all features input into the cross-scale layered feature fusion modules into n layers, composed of s feature mapping subsets, and fusing features of each feature mapping subset with that of other feature mapping subsets, and connecting; carrying out convolution operation, outputting training result; adjusting network parameters by a loss function to obtain parameters for a network model; inputting final output candidate boxes into a non-maximum suppression module to screen correct prediction boxes, so that prediction result is obtained.
    Type: Grant
    Filed: March 15, 2023
    Date of Patent: July 4, 2023
    Assignee: Ludong University
    Inventors: Jun Yue, Yifei Zhang, Qing Wang, Zhenbo Li, Guangjie Kou, Jun Zhang, Shixiang Jia, Ning Li
  • Publication number: 20230134182
    Abstract: Disclosed is a method for efficiently separating and purifying recombinant human coagulate factor VIII Fc fusion protein. The method comprises steps of affinity chromatography and anion exchange chromatography; and the sample captured by means of the affinity chromatography is eluted with a salt ion buffer containing 5%-20% polyol organic solvents under the condition of pH 4.0 to 8.0, and the protein sample can be separated and purified to 85% or more by further ProteinA affinity chromatography. The purification method is simple to operate, naturally connects each step of chromatography, has a high recovery rate and low cost, and easily increases production.
    Type: Application
    Filed: March 16, 2021
    Publication date: May 4, 2023
    Applicant: AMPSOURCE BIOPHARMA SHANGHAI INC.
    Inventors: Shixiang Jia, Shidong Xu, Lingju Yu, Bo Zhou, Hong Wu, Yonglong Yuan, Qiang Li
  • Publication number: 20230073411
    Abstract: A tetravalent, homodimer-type bispecific antibody molecule that simultaneously targets immune effector cell antigen CD3 and human epidermal growth factor receptor 2 (Her2); the bispecific antibody molecule comprises, from in sequence from N-terminus to C-terminus, a first single-chain Fv capable of specifically binding to Her2, a second single-chain Fv capable of specifically binding to CD3, and an Fc fragment; the first and second single-chain Fv are connected by means of a connection peptide, and the second single-chain Fv is connected to the Fc directly fragment or is connected by means of a connection peptide; the Fc fragment does not have effector functions such as CDC, ADCC and ADCP. The bispecific antibody may significantly inhibit or kill tumor cells, and has controlled toxic side effects that may be caused by excessive activation of effector cells.
    Type: Application
    Filed: October 28, 2019
    Publication date: March 9, 2023
    Applicants: AMPSOURCE BIOPHARMA SHANGHAI INC., AMPSOURCE BIOPHARMA SHANGHAI INC.
    Inventors: Qiang Li, Shixiang Jia, Xinlu Ma, Yuan Yan, Yuhua Zhang, Yuanli Li
  • Publication number: 20220033476
    Abstract: Disclosed is a fusion protein of a mutated recombinant single-chain human coagulation factor VIII (FVIII), a preparation method therefor, and a use thereof. The fusion protein sequentially comprises, from an N-terminus to a C-terminus, a mutated single-chain human FVIII having a partially deleted B-domain, a flexible peptide linker, at least one rigid unit of a carboxyl-terminal peptide of a human chorionic gonadotropin beta subunit, and a half-life prolonging moiety (preferably an IgG Fc variant). The fusion protein has a similar biological activity to a recombinant FVIII, a prolonged active half life in vivo, and better stability in vitro and in vivo, and thus improves the pharmacokinetics and efficacy of the fusion protein.
    Type: Application
    Filed: September 24, 2019
    Publication date: February 3, 2022
    Inventors: Yongjuan Gao, Shixiang Jia, Yuncheng Zheng, Yingying Jin, Zhu Wang, Zhao Dong, Si Chen, Bill Nai-chau Sun, Qiang Li
  • Publication number: 20220002431
    Abstract: Disclosed is a bispecific antibody that specifically binds to surface antigens CD3 of immune cells and CD20 antigens on the surfaces of tumor cells, and that can bind to human CD3 with high affinity, inducing T cell proliferation, and mediating tumor cell killing. The bispecific antibody in an in vitro test was able to mediate the specific killing of target cells by T cells. The construction method thereof is simple, avoiding the possibility of mismatch between two sets of light chains and heavy chains of heterobispecific antibodies, thereby reducing the difficulty of antibody purification. The affinity of the obtained antibody is high, the side effects caused by cytokines are small, and safety is high.
    Type: Application
    Filed: October 29, 2019
    Publication date: January 6, 2022
    Inventors: Qiang Li, Shixiang Jia, Xinlu MA, Xueyuan Cui, Yuhua Zhang, Si Chen
  • Publication number: 20220002407
    Abstract: Provided is a tetravalent, homodimer-type bispecific antibody molecule that targets both immune effector cell antigen CD3 and tumor-related antigen CD19. The bispecific antibody molecule comprises first and second single-chain Fv and Fc fragments in sequence from the N-terminus to the C-terminus, wherein the first single-chain Fv can specifically bind to CD19, the second single-chain Fv can specifically bind to CD3, the first and second single-chains Fv are connected by means of a linker peptide, the second single-chain Fv and Fc fragments are directly connected to each other or connected by means of a linker peptide; and the Fc fragment does not have effector functions such as CDC, ADCC, and ADCP.
    Type: Application
    Filed: October 31, 2019
    Publication date: January 6, 2022
    Inventors: Qiang Li, Shixiang Jia, Xinlu MA, Lili Zhao, Xueyuan Cui, Yuhua Zhang, Xuemei Liu, Guimin Zhang
  • Publication number: 20210383149
    Abstract: A method for identifying an individual of an oplegnathus punctatus based on a convolutional neural network is provided. Target initial positioning involves three continuous convolutional layers and an average pooling layer. A region of feature interest point is obtained, a hyperparameter candidate box is set to obtain a region, thereby obtaining an approximate position of a target object. II_Net backbone convolutional neural network includes six convolutional layers and four pooling layers, which includes a LeakyReLU activation function used as an activation function of the first convolutional layer, convolutional network layers of Alexnet and parameter data, and a maximum pooling layer of an overlapped pooling structure. Fully connected layers use a genetic algorithm to improve data transmission between layers. With the established model, identification of the individual of the oplegnathus punctatus is performed by using test data.
    Type: Application
    Filed: June 8, 2021
    Publication date: December 9, 2021
    Inventors: Jun Yue, Beibei Li, Shixiang Jia, Zhenbo Li, Qing Wang, Zheng Ma, Guangjie Kou, Tao Yao, Zhenzhong Li
  • Publication number: 20210371488
    Abstract: The present disclosure relates to a dual-function protein for regulating blood glucose and lipid metabolism, wherein said dual-function protein comprises a human GLP-1 analog and human FGF21. In the present disclosure, provided is a method for preparing said dual function protein, and also provided is the use of said dual-function protein in the preparation of a biological substance for treating type 2 diabetes, obesity, dyslipidemia, fatty liver disease and/or metabolic syndrome. The dual-function protein provided in the present disclosure can synergistically regulate blood glucose and lipid levels in vivo, and satisfy multiple requirements for patients with type 2 diabetes such as lowering blood glucose, relieving hepatic steatosis, reducing body weight and improving metabolic disorders of circulating lipids.
    Type: Application
    Filed: May 27, 2020
    Publication date: December 2, 2021
    Applicant: AMPSOURCE BIOPHARMA SHANGHAI INC.
    Inventors: Zhao DONG, Chi ZHOU, Xiong FENG, Jiyu ZHANG, Shixiang JIA, Qiang LI
  • Publication number: 20210371526
    Abstract: Provided is a tetravalent homodimeric bispecific antibody molecule simultaneously targeting an immune effector cell antigen CD3 and a tumor-associated antigen, wherein the bispecific antibody molecule contains, in order from N-terminus to C-terminus, a first single chain Fv, a second single chain Fv and a Fc fragment; wherein the first single chain Fv can specifically bind to the tumor-associated antigen, the second single chain Fv can specifically bind to CD3, and the first and the second single chain Fvs are connected by a linker peptide, while the second single chain Fv and the Fc fragment are directly connected or connected by a linker peptide; and the Fc fragment does not have effector functions such as CDC, ADCC and ADCP.
    Type: Application
    Filed: October 31, 2019
    Publication date: December 2, 2021
    Inventors: Qiang Li, Xinlu Ma, Shixiang Jia, Yuan Yan, Yuhua Zhang, Li Zhou, Rilong Sun, Xueyuan Cui, Lingju Yu, Yujie Yan, Yingying Jin, Yao Xiong, Yuanli Li, Si Chen, Xuemei Liu, Jiasheng Diao